What’s the current market cap for Gubra A/S stock?

Gubra A/S (GUBRA) has a market cap of DKr5.7bn as of June 18, 2026.

What is the P/E ratio for Gubra A/S stock?

The price to earnings (P/E) ratio for Gubra A/S (GUBRA) stock is 3.4 as of June 18, 2026.

Does Gubra A/S stock pay dividends?

Yes, the Gubra A/S (GUBRA) stock pays dividends to shareholders. As of June 18, 2026, the dividend rate is DKr61.2 and the yield is 17.54%. Gubra A/S has a payout ratio of 0% on a trailing twelve-month basis.

When is the next Gubra A/S dividend payment date?

The next Gubra A/S (GUBRA) dividend payment date is unconfirmed.

What is the beta indicator for Gubra A/S?

Gubra A/S (GUBRA) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Gubra A/S stock | DKrGUBRA Share Price

About Gubra A/S

Gubra A/S is a biotechnology company based in Denmark, focusing on pre-clinical contract research and drug discovery. It specializes in the development of peptide-based therapeutics and provides services in areas such as obesity, diabetes, and NASH (non-alcoholic steatohepatitis). The company was founded in 2008 and operates from its headquarters in Hørsholm, Denmark. Gubra differentiates itself through its integrated approach combining histology, imaging, and bioinformatics to deliver comprehensive research services. Its strategic positioning leverages cutting-edge technology to support pharmaceutical companies in early-stage drug development.

Ticker

DKr GUBRA

Sector

Health

Primary listing

CSE

Employees

300

Headquarters

Horsholm, Denmark

Website

www.gubra.dk

Gubra A/S Metrics

BasicAdvanced

kr 5.7bn

3.40

kr 102.70

0.27

kr 61.20

17.54%

Bulls say / Bears say

Gubra delivered record FY 2025 financial results, with revenue reaching DKK 2.6 billion and net profit of DKK 1.7 billion, driven by a $350 million upfront from AbbVie under a $2.2 billion outlicensing agreement for ABBV-295, transforming its Discovery & Partnerships segment to profitability. (Investing.com)

Despite distributing DKK 1.0 billion in dividends, Gubra ended 2025 with DKK 1.1 billion in liquidity, providing a strong cash buffer to fund R&D investments and strategic initiatives. (Investing.com)

Gubra advanced its clinical pipeline de-risking milestones by submitting a CTA for its lead internal asset GUB-UCN2 (expected clinical entry H1 2026) and seeing its partnered obesity programs ABBV-295 and BI 3034701 progress toward Phase 2 development in mid-2026. (MarketScreener)

Gubra’s CRO segment revenue declined 5% year-over-year in the first nine months of 2025, prompting management to cut full-year 2025 CRO revenue guidance to 5–10% below 2024 levels, underscoring persistent macroeconomic headwinds in its pre-clinical services business. (TradingView News)

In Q3 2025, Gubra reported an adjusted EBIT loss of DKK 6.1 million versus a small profit in the prior year, reflecting margin pressure and profitability challenges in its core CRO operations. (TradingView News)

Despite record 2025 results, Gubra’s share price at DKK 330 on February 27 remained over 50% below its 52-week high of DKK 730, indicating investor skepticism about the sustainability of milestone-driven growth without repeat outlicensing transactions. (Investing.com)

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

About Gubra A/S

Ticker

Primary listing

Employees

Headquarters

Gubra A/S Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy DKr GUBRA

Lightyear

Legal

Work with us

Bulls say / Bears say

Gubra A/S/DKr GUBRA

About Gubra A/S

Ticker

Primary listing

Employees

Headquarters

Gubra A/S Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

What’s the current market cap for Gubra A/S stock?

What is the P/E ratio for Gubra A/S stock?

Does Gubra A/S stock pay dividends?

When is the next Gubra A/S dividend payment date?

What is the beta indicator for Gubra A/S?

Bulls say / Bears say